1 unchanged sentence
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements.
−Removed: During the quarter ended June 30, 2024, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
+Added: During the quarter ended September 30, 2024, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
4 unchanged sentences
001-37581), filed with the SEC on June 24, 2020).
−Removed: Royalty Purchase Agreement, effective as of July 16, 2024, by and between the Registrant and OCM IP Healthcare Portfolio LP.
+Added: Royalty Purchase Agreement, effective as of July 16, 2024, by and between the Registrant and OCM IP Healthcare Portfolio LP (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-37581), filed with the SEC on August 7, 2024).
Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.
11 unchanged sentences
Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
−Removed: Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company has determined that the information is both not material and is the
−Removed: type that the Company treats as private or confidential.
+Added: Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company has determined that the information is both not material and is the type that the Company treats as private or confidential.
The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of the exhibit.
3 unchanged sentences
ACLARIS THERAPEUTICS, INC.
−Removed: August 7, 2024
+Added: November 6, 2024
/s/ Neal Walker
1 unchanged sentence
(On behalf of the Registrant)
−Removed: August 7, 2024
+Added: November 6, 2024
/s/ Kevin Balthaser
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.